1stOncology™: Cancer Intelligence Service – Page 8791 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

IntegraGen reports sales of 4.8 M€ for the first half of 2021, a 2% increase versus 2020, and a cash position of 4.3 M€

On July 16, 2021 IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in decoding the human genome which performs interpretable genomic analyzes for academic and private laboratories, reported its unaudited turnover for the first half of 2021 (Press release, Integragen, JUL 16, 2021, View Source [SID1234585219]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The unaudited first half turnover amounted to 4,816 k€, up 2% compared to the first half of 2020 (4,706 k€). This growth was achieved despite the sharp slowdown in general economic activity during the first half of 2021 compared with H1 2020, whose first quarter was less affected by the pandemic. This sustained growth demonstrates the robustness of IntegraGen’s business model.

R&D sequencing activities continued to progress at a moderate pace, driven by whole genome sequencing projects performed for the European customers. While sequencing activities associated with the external platforms operated by IntegraGen benefited from the demand of sequencing projects linked to the pandemic, oncology-related clinical research activities, in particular the sales of interpretation software, slowed significantly for the same reason.

The company’s cash position at the end of June 2021 was 4,272 k€, a decrease of nearly 850 k€ compared to the cash position as of December 31, 2020. This variation was due to change in working capital requirements and investments, particularly in the company’s quality systems to obtain several certifications which will lead to increase revenues generated from customers in regulated industries.

Finally, the orders booked as of June 30, 2021 were significantly higher compared to the same period of 2020, setting the stage for a sustained growth in activities during the second half of 2021. The integration of IntegraGen into the OncoDNA Group, which acquired a majority of the company’s shares in 2020 through a friendly takeover bid, also enhances the prospects for IntegraGen’s additional sales growth as a result of the ability to leverage the Group’s subsidiaries and distributors.

Bernard Courtieu, CEO of IntegraGen, said: "The business we generated during the first half of 2021 confirms that despite the ongoing pandemic that continues to disrupt our activities, the trajectory of our revenue growth is sustainable, albeit at a lower level, with prospects for a significant recovery. The acquisition of a majority of the company’s shares by the Belgian company OncoDNA results in commercial and operational synergies which will enable IntegraGen to continue its development and growth as a vital part of the OncoDNA Group."

The financial results for the first half of 2021 will be published on October 8, 2021.

Hailai Xinchuang Closes $77 Million Round for Tumor Treating Fields Device

On July 16, 2021 Jiangsu Hailai Xinchuang Medical Technology reported that it closed a $77 million Series C funding to advance its Tumor Treating Fields (TTF) electrical pulse technology for cancer (Press release, Jiangsu Hailai Xinchuang Medical Technology, JUL 16, 2021, View Source [SID1234584924]). TTF is designed to interfere with cancer cell division. Hailai has started a multi-center China clinical trial of EFE-G100 in glioblastoma patients, with positive initial results. The company will report an interim analysis from the data in 2022. The latest funding was led by YF Capital, with participation from Temasek, Lilly Asia Ventures, 3H Health Investment, CITIC and Qiming.

Vertex to Announce Second-Quarter 2021 Financial Results on July 29

On July 16, 2021 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that it will report its second-quarter 2021 financial results on Thursday, July 29, 2021 after the financial markets close. The company will host a conference call and webcast at 5:30 p.m. ET (Press release, Vertex Pharmaceuticals, JUL 16, 2021, View Source [SID1234584921]). To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).

The conference call will be webcast live and a link to the webcast can be accessed through Vertex’s website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the company’s website.

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

On July 16, 2021 Celldex Therapeutics, Inc. ("Celldex" or the "Company") (Nasdaq: CLDX) reported the closing of its previously announced underwritten public offering of 6,845,238 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase an additional 892,857 shares, at a public offering price of $42.00 per share (Press release, Celldex Therapeutics, JUL 16, 2021, View Source [SID1234584920]). The gross proceeds to Celldex from this offering were approximately $287.5 million, before deducting underwriting discounts and commissions and offering expenses.

Jefferies, SVB Leerink, Guggenheim Securities and Cantor acted as joint book-running managers for the offering. LifeSci Capital LLC and H.C. Wainwright & Co. acted as co-lead managers for the offering.

The securities described above were offered and sold by Celldex pursuant to a prospectus supplement and an accompanying base prospectus forming part of a shelf registration statement on Form S-3 (File No. 333-249917), which was deemed effective by the Securities and Exchange Commission ("SEC") on November 6, 2020, and are available on the SEC’s website located at View Source Copies of the prospectus supplement and the accompanying base prospectus may be obtained for free by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by e-mail at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525, ext. 6105, or by e-mail at [email protected]; or Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-9544, or by email at [email protected]; or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Grit Bio Closes Series A+ Round for its Cell Therapy Oncology Therapies

On July 16, 2021 Grit Biotechnology, a two-year-old Shanghai cell therapy company, reported that it closed a Series A+ round to develop its Tumor Infiltrating Lymphocytes (TIL) therapies (Press release, Grit Bio, JUL 16, 2021, View Source [SID1234584915]). Its leading program is GT101, a genetically unmodified TIL product that is currently being tested at a multi-centered clinical trial in China for solid malignancy indications. The round was led by GL Ventures, the VC arm of Hillhouse Group, with participation from Apricot Capital and Junshi Bio, as well as continued support from existing shareholders, Decheng Capital and Matrix Partners.